In Season 2 Episode 16, a discussion of cost-effectiveness led to the question, “How will treatment pathways and rules evolve as new NASH drugs come to market.” Mazen Noureddin, who raised this issue with Stephen Harrison in the earlier episode, returns to explore the answer ten episodes later.
The discussion considers what the phrase “backbone therapy” will mean in the future of NASH therapy and which agent(s) might attain that status. It considers how treatment models might vary for patients with cirrhosis vs. those with NASH, and for compensated cirrhosis vs. decompensated cirrhosis. It explores the role that AI-driven algorithms powered through electronic records will play in helping primary care physicians, general gastroenterologists and general hepatologists (if there is such a thing) treat patient who might have not only NASH but a range of accompanying metabolic conditions.
This discussion covers a lot of ground in a very short time. It stimulates and challenges. Enjoy it!
TOPICS: 89bio, Akero Therapeutics, aldafermin, Bristol-Myers Squibb, cirrhosis, Diabetes, Diagnostic Tests, Digital Health, efruxifermin, Fatty Liver, FGF-21, FIB-4, Fibrosis Level 3, Fibrosis Level 4, Intercept Pharmaceuticals, inventiva, lanifibranor, Lean NASH, Madrigal, MRI-PDFF, NAFLD, NASH, NGM Biopharmaceuticals, non-invasive liver testing, Novo Nordisk, Obesity, obeticholic acid, OCA, Perspectum Diagnostics, population screening, seladelpar, Semaglutide, Treatment pathways, guidelines, Artificial Intelligence, electronic health records, resmetirom, public health, metformin, statins, GLP-1s
Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast